The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study by Connolly, S. J. et al.
237
Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation 
Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or 
systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran 
and for further data comparing the 2 dabigatran doses.
Methods and Results—Patients randomly assigned to dabigatran in RE-LY were eligible for the Long-term Multicenter 
Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial if they had not permanently 
discontinued study medication at the time of their final RE-LY study visit. Enrolled patients continued to receive the 
double-blind dabigatran dose received in RE-LY, for up to 28 months of follow up after RE-LY (median follow-up, 
2.3 years). There were 5851 patients enrolled, representing 48% of patients originally randomly assigned to receive 
dabigatran in RE-LY and 86% of RELY-ABLE–eligible patients. Rates of stroke or systemic embolism were 1.46% and 
1.60%/y on dabigatran 150 and 110 mg twice daily, respectively (hazard ratio, 0.91; 95% confidence interval, 0.69–1.20). 
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Atrial fibrillation (AF) is a common condition that increases the risk of thrombus in the left atrial append-
age and that is strongly associated with an increased risk of 
ischemic stroke.1 Antithrombotic medications, which inhibit 
either platelet activity or coagulation, reduce this risk.2 Until 
recently, the most effective antithrombotic agents were the 
vitamin K antagonists, such as warfarin, although a narrow 
therapeutic window, high intra- and interpatient variability, 
need for therapeutic monitoring, and concern about bleed-
ing have limited their use.3 Recently, the direct thrombin 
inhibitor dabigatran and inhibitors of Factor Xa have been 
evaluated in large phase III clinical trials with an average 
follow-up of ≈2 years.4–7
Editorial see p 200 
Clinical Perspective on p 243
Dabigatran etexilate is a prodrug with rapid conversion to the 
active metabolite, dabigatran, in the circulation. It has a half-life 
or 12 to 17 hours and has 80% renal elimination. There are few 
drug–drug interactions, and it has a broad therapeutic window 
at fixed doses and no need for anticoagulant monitoring. The 
Randomized Evaluation of Long-term Anticoagulation Therapy 
(RE-LY) trial randomly assigned 18 113 patients with AF and 
with at least 1 risk factor for stroke to receive either of 2 blinded 
fixed doses of dabigatran (110 mg or 150 mg twice daily) or 
unblinded, adjusted-dose warfarin. RE-LY demonstrated that 
dabigatran 150 mg twice daily was superior to warfarin for the 
prevention of stroke or systemic embolism and that dabiga-
tran 110 mg twice daily was noninferior.4 Both doses greatly 
reduced hemorrhagic stroke, and dabigatran 110 mg twice daily 
significantly reduced major bleeding in comparison with war-
farin. These findings led to the regulatory approval of dabiga-
tran for patients with AF in 81 countries. The mean duration of 
follow-up in RE-LY was 2.0 years with a maximum follow-up 
of up to 3 years. Little is known of the consistency of effects of 
dabigatran during longer periods of follow-up.
Regulatory agencies in different countries have taken dif-
ferent positions regarding the approval of dabigatran 150 
and 110 mg and their use in specific patient subgroups.8 
Further information comparing the 2 doses of dabigatran 
would be useful.
The Long-term Multicenter Extension of Dabigatran 
Treatment in Patients with Atrial Fibrillation (RELY-ABLE) 
study was designed to provide additional information on 
the long-term effects of the 2 doses of dabigatran in patients 
completing RE-LY by extending the follow-up of patients on 
dabigatran from a mean of 2 years at the end of RE-LY by an 
additional 2.25 years.
Methods
Patient Eligibility
Patients were eligible for RELY-ABLE if they were participating in 
RE-LY, randomly assigned to double-blinded dabigatran study medi-
cation, and not permanently discontinued from study medication at 
the time of the final RE-LY study visit. Exclusion criteria reassessed 
at the time of enrollment into RELY-ABLE included the need for 
anticoagulant treatment for disorders other than AF, a plan to perform 
pulmonary vein ablation or surgery for AF, documented gastrointesti-
nal ulcer disease in the 30 days before the start of the trial, estimated 
creatinine clearance ≤30 mL/min, anemia (hemoglobin <100 g/L), 
thrombocytopenia (platelet count <100×109/L). Patients provided 
written informed consent. After enrollment in RELY-ABLE, patients 
continued to receive the same dose of dabigatran, double-blind, that 
they had received during RE-LY. Patients randomly assigned to war-
farin in RE-LY were not eligible for RELY-ABLE.
Patient Follow-Up
The final RE-LY study visits occurred between December 15, 2008 
and March 15, 2009. It was intended that patients would begin study 
treatment in RELY-ABLE without interruption at their final RE-LY 
study visit; however, the protocol allowed for an interruption of 
dabigatran treatment for up to 8 weeks after the final RE-LY study, 
during which time they would be treated with other anticoagula-
tion therapy. The RELY-ABLE study follow-up visits occurred at 4, 
8, 13, 18, and 23 months, and the final visit occurred at 28 months 
after their study enrollment visit. In some countries where dabi-
gatran was not yet approved at the time of the 28-month visit, the 
trial was extended, and continued follow-up information was col-
lected in patients (n=2188) who continued to receive blinded study 
medication. Follow-up beyond the 28-month visit is not included in 
this analysis. Patients who permanently discontinued study medica-
tion in RELY-ABLE were scheduled for a final visit, at which point 
follow-up was stopped (vital status, however, was collected at study 
conclusion in all patients). Laboratory sampling was performed at 
the 0-, 8-, 18-, and 28-month visits and included the evaluation of 
liver and kidney function. Patients discontinued therapy if, during the 
trial, their estimated creatinine clearance decreased to <30 mL/min; 
but they could have it restarted if the estimated creatinine clearance 
returned to ≥30 mL/min.
Outcome Events
The study outcomes of RELY-ABLE were the same as those of 
RE-LY4: stroke (ischemic or hemorrhagic), systemic embolism, myo-
cardial infarction, pulmonary embolism, vascular death, and total 
mortality. Safety outcomes included major, life-threatening, minor, 
and total bleeding, and deep vein thrombosis. Net clinical benefit 
was defined as a composite of the following events: stroke, systemic 
embolism, myocardial infarction, pulmonary embolism, death, or 
major bleeding. Major bleeding was defined as bleeding associated 
with a reduction in hemoglobin of at least 20 g/L or leading to a 
transfusion of at least 2 units of blood or packed cells or symptomatic 
bleeding into a critical area or organ. Major bleeds were classified as 
life-threatening if they met any of the following criteria: fatal, symp-
tomatic, intracranial, hemoglobin reduction ≥50 g/L, transfusion ≥ 4 
Rates of major hemorrhage were 3.74% and 2.99%/y on dabigatran 150 and 110 mg (hazard ratio, 1.26; 95% confidence 
interval, 1.04–1.53). Rates of death were 3.02% and 3.10%/y (hazard ratio, 0.97; 95% confidence interval, 0.80–1.19). 
Rates of hemorrhagic stroke were 0.13% and 0.14%/y.
Conclusions—During 2.3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major 
bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00808067. (Circulation. 
2013;128:237–243.)
Key Words: atrial fibrillation ◼ dabigatran ◼ hemorrhage ◼ stroke
 by guest on February 13, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Connolly et al  RELY-ABLE  239
U, associated with hypotension requiring intravenous inotropic agents 
or necessitating surgical intervention. Minor bleeds were any other 
clinical bleeds that did not fill the criteria for major bleeds. There was 
no adjudication of outcome events occurring in RELY-ABLE.
Statistical Analysis
There was no primary outcome for RELY-ABLE because the study 
was descriptive. The statistical analysis describes the outcomes of 
patients on the 2 doses of dabigatran and compares their efficacy and 
safety. Cox proportional hazards modeling was used to compare the 
outcomes between patients receiving dabigatran 110 and 150 mg. 
Data analysis included only patients enrolled in RELY-ABLE from 
the time of enrollment in RELY-ABLE until the 28-month visit.
A total of 5891 patients were entered in RELY-ABLE, of whom 8 did 
not receive a single study dose, and 32 others were excluded from the 
analysis because of serious protocol violations during RELY-ABLE at 
their clinical centers. The data set for the analysis of the RELY-ABLE 
cohort included 5851 patients. There were 695 patients enrolled into 
RELY-ABLE after the RE-LY final visit was completed (342 and 353 on 
dabigatran 110 and 150 mg, respectively). Of these, 369 patients were 
enrolled in RELY-ABLE within 4 weeks and 326 others between 4 and 
8 weeks beyond the RE-LY final visit. No strokes or deaths and 3 major 
bleeds occurred in these patients during the interim period between 
the 2 studies. This period is not included in the RELY-ABLE analysis. 
Baseline characteristics of RE-LY patients enrolled and not enrolled in 
RELY-ABLE receiving dabigatran 110 mg or 150 mg were compared 
by using the Student t test or χ2 tests as appropriate; in addition, the 
probability value for RE-LY treatment interaction was calculated.
Study Conduct
The study was sponsored by Boehringer-Ingelheim and was coor-
dinated at the Population Health Research Institute at McMaster 
University in Hamilton, Ontario, which independently managed the 
database and performed the primary data analysis. An operations group 
with assistance from an international steering committee and with 
participation by the sponsor was responsible for the design, conduct, 
and reporting of the study. The study was approved by all appropriate 
national regulatory authorities and ethics committees of the participat-
ing centers. The study was approved by an institutional review com-
mittee at each site, and all subjects gave informed consent. The authors 
had complete access to the primary clinical trial data. The trial was 
registered at clinicaltrials.gov (unique identifier: NCT00808067).
Results
Table 1 shows the disposition of patients randomly assigned to 
dabigatran from the beginning of RE-LY to the 28-month visit 
in RELY-ABLE. There were 403 (13.8%) patients on dabiga-
tran 110 mg and 429 (14.6%) patients on dabigatran 150 mg 
twice daily who permanently discontinued their study medi-
cation before the 28-month study visit of RELY-ABLE. The 
Kaplan-Meier estimates of the time to permanent study medi-
cation discontinuation at 2 years were 11.0% (95% confidence 
interval [CI], 9.9%–12.2%) for dabigatran 110 mg and 11.9% 
(95% CI, 10.8%–13.2%) on dabigatran 150 mg (Figure II in 
the online-only Data Supplement). There were 2188 patients 
who continued to receive study medication and to participate 
in RELY-ABLE beyond the 28-month visit. (This was done to 
continue safety follow-up in countries where the drug was not 
yet available commercially.) The median duration of follow-up 
for RELY-ABLE patients (up to the 28-month visit) was 2.3 
years. The longest duration of follow-up of any patient receiv-
ing dabigatran, from the beginning of RE-LY to the 28-month 
visit of RELY-ABLE, was 5.5 years. During RELY-ABLE, 
there were temporary interruptions of study medication in 
1244 (43%) patients receiving dabigatran 110 mg and in 1294 
(44%) patients receiving dabigatran 150 mg. The most com-
mon reasons for these interruptions were surgery and hospital-
ization (48% and 18% of interruptions, respectively).
Patient Characteristics
The RE-LY baseline clinical characteristics of patients par-
ticipating in RELY-ABLE, in general, were similar to those 
of patients not participating in RELY-ABLE, but there were 
some significant differences (Table 2). Patients who enrolled in 
RELY-ABLE were more likely to be male and to have parox-
ysmal rather than permanent AF and less likely to have a his-
tory of heart failure, but they had rates of diabetes mellitus and 
documented coronary disease similar to other RE-LY patients. 
The evaluation of baseline clinical characteristics of enrolled 
and not enrolled patients according to dabigatran dose (Table 2) 
showed no systematic differences between doses for any of the 
baseline clinical characteristics. Patients who were enrolled in 
RELY-ABLE were also less likely to have had a major clinical 
event during the RE-LY study in comparison with patients who 
participated in RE-LY but did not continue in RELY-ABLE. 
Table I in the online-only Data Supplement shows baseline 
characteristics that were reassessed at the time of enrollment 
into RELY-ABLE (1–3 years after enrollment into RE-LY).
During RELY-ABLE (Table 3 and Figure 1), the annual 
rates of stroke or systemic embolism were 1.46% and 1.60%/y 
Table 1. Patient Disposition in RE-LY and RELY-ABLE
Dabigatran 150 mg Dabigatran 110 mg
Randomized to dabigatran in RE-LY 6076 6015
Completed RE-LY alive and still receiving study 
dabigatran
4519 4492
Patient followed at site participating in RELY-ABLE 3397 3395
Patient enrolled in RELY-ABLE * 2937 2914
Completed RELY-ABLE still receiving study medication† 2508 2511
Continued in RELY-ABLE beyond the 28-month visit‡  1102 1086
The study was performed in 35 countries at 598 clinical centers. The geographic distribution of patients was 38% from Canada or United States, 33% from 
Western Europe, 12% from Asia, 11% from Central Europe, 6% from Australia and Israel, and 1% from Brazil. RE-LY indicates Randomized Evaluation of Long-term 
Anticoagulation Therapy; and RELY-ABLE, Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation.
*Does not include 8 patients who received no dose of study medication in RELY-ABLE and 32 patients treated at sites with serious Good Clinical Practice violations.
†Either patient died or completed 28-month RELY-ABLE visit without permanent study medication discontinuation.
‡Available for patients in countries where the RELY-ABLE trial was extended beyond the 28-month visit'
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on dabigatran 150 and 110 mg, respectively (hazard ratio 
[HR], 0.91; 95% CI, 0.69–1.20). Annual rates of ischemic 
stroke (including stroke of uncertain cause) were 1.15% and 
1.24%/y on dabigatran 150 and 110 mg, respectively (HR, 
0.92; 95% CI, 0.67–1.27). Annual rates of hemorrhagic stroke 
were similar in the 2 treatment arms and were very low at 
0.13% and 0.14%/y on dabigatran 150 and 110 mg, respec-
tively. Annual rates of myocardial infarction were also low 
and similar between the 2 groups at 0.69% and 0.72%/y.
Annual rates of major bleeding (Table 4 and Figure 2) were 
3.74% and 2.99%/y on dabigatran 150 and 110 mg twice daily, 
respectively (HR, 1.26; 95% CI, 1.04–1.53). Annual rates of 
Table 2. RE-LY Baseline Patient Characteristics and Clinical Events During RE-LY
RE-LY Patients Not  
Enrolled in RELY-ABLE
RE-LY Patients Enrolled  
in RELY-ABLE P-Values
150 mg
(n=3139)
110 mg
(n=3101)
150 mg
(n=2937)
110 mg
(n=2914)
Enrolled vs  
Not Enrolled
110 vs 
150 mg
Age, y, mean (SD) 72 (9) 72 (9) 71 (8) 71 (8) 0.001 0.55
Systolic BP-sitting, mm Hg; mean (SD) 131 (18) 131 (18) 131 (18) 131 (18) 0.20 0.46
Heart rate, beats/min; mean (SD) 74 (15) 75 (15) 73 (15) 73 (15) <0.001 0.08
Male, n (%) 1929 (62) 1951 (63) 1911 (65) 1914 (66) 0.03 0.64
AF diagnosed >2 y; nr (%) 1503 (48) 1463 (47) 1373 (47) 1380 (47) 0.89 0.47
Persistent AF, n (%) 1004 (32) 1017 (33) 905 (31) 933 (32) 0.52 0.81
Paroxysmal AF, n (%) 912 (29) 905 (29) 1066 (36) 1024 (35) <0.001 0.47
Permanent AF, n (%) 1222 (39) 1177 (38) 966 (33) 955 (33) <0.001 0.64
Prior stroke or TIA, n (%) 611 (20) 614 (20) 622 (21) 581 (20) 0.89 0.28
Vitamin K antagonist experienced, n (%) 1524 (49) 1475 (48) 1525 (52) 1536 (53) <0.001 0.33
History of hypertension, n (%) 2505 (80) 2417 (78) 2290 (78) 2321 (80) 0.11 0.02
History of myocardial infarction, n (%) 551 (18) 542 (18) 478 (16) 466 (16) 0.12 0.87
History of heart failure, n (%) 1121 (36) 1147 (37) 813 (28) 790 (27) <0.001 0.29
History of diabetes mellitus, n (%) 765 (24) 734 (24) 637 (22) 675 (23) 0.64 0.15
History of CAD, n (%) 878 (28) 868 (28) 832 (28) 793 (27) 0.50 0.49
CHADS
2 risk score, mean (SD) 2.2 (1.1) 2.2 (1.1) 2.1 (1.1) 2.1 (1.1) <0.001 0.32
Baseline use of β-blocker, n (%) 1892 (60) 1853 (60) 1980 (67) 1931 (66) <0.001 0.68
Baseline use of statin, n (%) 1293 (41) 1292 (42) 1374 (47) 1406 (48) <0.001 0.60
Baseline use of ARB or ACE inhibitor, n (%) 2118 (68) 2043 (66) 1935 (66) 1944 (67) 0.52 0.16
Events occurring during RE-LY
 Major bleed, event number (rate/y) 309 (5.3) 251 (4.3) 91 (1.5) 91 (1.5) <0.001 0.21
 Stroke, event number (rate/y) 106 (1.8) 140 (2.4) 17(0.3) 31 (0.5) <0.001 0.33
 Myocardial infarction, event number (rate/y) 67 (1.1) 60 (1.0) 22 (0.3) 28 (0.5) <0.001 0.29
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; CAD, coronary artery disease; CHADS
2; 
RE-LY, Randomized Evaluation of Long-term Anticoagulation Therapy; RELY-ABLE, Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial 
Fibrillation; SD, standard deviation; and TIA, transient ischemic attack.
Table 3. Stroke, Ischemic Outcomes, and Hospitalizations
150 mg
n (%/y)
110 mg
n (%/y)
HR
(150 mg vs 110 mg) 95% CI
Stroke or systemic embolism 93 (1.46) 102 (1.60) 0.91 0.69–1.20
All stroke 79 (1.24) 88 (1.38) 0.89 0.66–1.21
Ischemic or type uncertain 73 (1.15) 79 (1.24) 0.92 0.67–1.27
Hemorrhagic 8 (0.13) 9 (0.14) 0.89 0.34–2.30
Nondisabling (modified Rankin score 0–2) 36 (0.57) 49 (0.77) 0.73 0.48–1.13
Disabling (modified Rankin score 3–5) or fatal 40 (0.63) 39 (0.61) 1.03 0.66–1.59
Myocardial infarction 44 (0.69) 46 (0.72) 0.96 0.63–1.45
Pulmonary embolism 8 (0.13) 7 (0.11) 1.14 0.41–3.15
Cardiovascular hospitalization 634 (9.96) 619 (9.74) 1.03 0.92–1.15
Any hospitalization 1204 (18.9) 1170 (18.4) 1.04 0.96–1.12
CI indicates confidence interval; HR, hazard ratio; and %/y, rate per 100 patient-years of follow-up.
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major gastrointestinal bleeding were similar between treat-
ments at 1.54% and 1.56%/y for dabigatran 150 and 110 mg, 
respectively. Mortality rates were similar for the 2 dabigatran 
doses (3.10% and 3.02%/y for 110 and 150 mg, respectively) 
with a hazard ratio very close to unity (HR=0.97) (Figure 3).
During RELY-ABLE, serious adverse events occurred in 
1067 (36.3%) and 982 (33.7%) patients receiving dabigatran 
150 and 110 mg, respectively. Dyspeptic symptoms were 
reported in 141 (4.8%) and 156 (5.3%) of patients receiving 
dabigatran 110 and 150 mg, respectively, during the RELY-
ABLE follow-up (see Figure I and Table II in the online-only 
Data Supplement, showing time to first serious adverse event 
and serious adverse events by organ class, respectively). 
Elevation of the aspartame aminotransferase or of the alanine 
aminotransferase >3 times the upper limit of normal, together 
with elevation of the total bilirubin >2 times the upper limit 
of normal occurred during RELY-ABLE in 4 and 1 patients 
receiving dabigatran 110 and 150 mg, respectively.
Discussion
For both dabigatran 110 mg and 150 mg twice daily, the rates 
of major ischemic, hemorrhagic, and fatal outcomes that 
occurred during an additional period of 2.3 years following 
RE-LY are not inconsistent with those seen during RE-LY. The 
mean period of follow-up for RE-LY and RELY-ABLE receiv-
ing dabigatran was 4.3 years; some patients on dabigatran 
were followed for up to 5.5 years. It is particularly noteworthy 
that the very low rates of hemorrhagic stroke and intracranial 
bleeding observed in RE-LY continued to be observed during 
the extended follow-up period.
Rates of stroke or systemic embolism, on dabigatran 150 
and 110 mg, were 1.11% and 1.54%/y in RE-LY and 1.46% 
and 1.60%/y in RELY-ABLE. The slightly higher rates in 
RELY-ABLE are at least partly because there was no event 
adjudication in RELY-ABLE. In RE-LY, adjudication either 
confirmed reported events or rejected them (84% and 87% 
of reported stroke or systemic emboli on dabigatran 150 and 
110 mg, respectively, were confirmed). It may also be, in part, 
attributable to the increased age of patients during RELY-
ABLE follow-up. Rates of major bleeding on dabigatran 150 
and 110 mg were 3.32% and 2.87%/y in RE-LY and 3.74% and 
2.99%/y in RELY-ABLE (adjudication in RE-LY confirmed 
93% of reported major bleeds on both doses). Rates of hem-
orrhagic stroke and myocardial infarction remained very low 
in RELY-ABLE, <0.14%/y and <0.71%/y, respectively; very 
similar to the rates seen in RE-LY. This provides reassurance 
Figure 1. Stroke or systemic embolism.
Table 4. Bleeding and Net Benefit Outcomes
150 mg n (%/y) 110 mg n (%/y)
HR
(150 mg vs 110 mg) 95% CI
Major bleeding 238 (3.74) 190 (2.99) 1.26 1.04–1.53
 Life-threatening 114 (1.79) 100 (1.57) 1.14 0.87–1.49
 Gastrointestinal 98 (1.54) 99 (1.56) 0.99 0.75–1.31
 Intracranial 21 (0.33) 16 (0.25) 1.31 0.68–2.51
 Extracranial 218 (3.43) 179 (2.82) 1.23 1.01–1.49
 Fatal 15 (0.24) 16 (0.25) 0.94 0.46–1.89
Minor bleeding 617 (9.70) 521 (8.19) 1.21 1.07–1.36
Net clinical benefit outcomes
 Total mortality 192 (3.02) 197 (3.10) 0.97 0.80–1.19
 Vascular mortality 106 (1.67) 103 (1.62) 1.03 0.78–1.35
 Disabling stroke, life-threatening bleed, or death 288 (4.53) 283 (4.45) 1.02 0.86–1.20
  Stroke, systemic embolism, myocardial infarction, 
pulmonary embolism, major bleed, or death
468 (7.36) 438 (6.89) 1.07 0.94–1.22
CI indicates confidence interval; and HR, hazard ratio.
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that the effects of dabigatran seen during RE-LY are not incon-
sistent with those seen during longer-term treatment.
Only about half of the dabigatran patients participating in 
RE-LY were enrolled in RELY-ABLE. Many patients were not 
eligible owing to medication discontinuation during RE-LY or 
to nonparticipation of the clinical site. Enrollment rates at par-
ticipating sites, among eligible patients, were high (86%). There 
does not appear to be any bias in enrollment for RELY-ABLE 
based on dabigatran dose. There were almost equal numbers of 
patients enrolled in RELY-ABLE on each blinded dose, and sta-
tistical testing to determine interaction between dabigatran dose 
and patient characteristics of patients enrolled in RELY-ABLE 
(versus not enrolled) were not significant. It is not surprising 
that patients entering RELY-ABLE were less likely to have had 
either a stroke or bleed (or death) during RE-LY than those who 
did not enter RELY-ABLE. Patients with major events dur-
ing RE-LY would be more likely to die or discontinue study 
medication during RE-LY (making them ineligible for RELY-
ABLE). Once enrolled in RELY-ABLE, however, the ischemic 
and hemorrhagic event rates of these patients were very similar 
to those of the overall RE-LY population, suggesting the intrin-
sic risk for events of the RELY-ABLE patients differed little 
from that of the other RE-LY patients.
In RE-LY, randomized comparison of the 2 doses of dabi-
gatran demonstrated that the 150-mg dose reduced ischemic 
(or unspecified) stroke in comparison with the 110-mg dose 
(HR, 0.69; 95% CI, 0.54–0.88; P=0.002), but with a trend 
to increased major bleeding (HR, 1.16; 95% CI, 1.00–1.34; 
P=0.04). The mortality (HR, 0.97; 95% CI, 0.85–1.11; 
P=0.66) and the rate of hemorrhagic stroke, as well, was simi-
lar between the dabigatran doses in RE-LY.4,5 In RELY-ABLE, 
the relative advantage of the higher dose over the lower dose 
for ischemic stroke was small (HR, 0.92; 95% CI, 0.67–1.27). 
There was, however, a higher rate of major bleeding with the 
higher dose of dabigatran in comparison with the 110 mg 
twice daily dose (HR, 1.26; 95% CI, 1.04–1.53). There was no 
difference in mortality between the 2 doses either in RE-LY 
or in RELY-ABLE. Likewise, analysis of the composite of all 
major ischemic, hemorrhagic, and fatal events as a measure 
of net benefit indicates that the 2 doses achieve similar net 
clinical effects. The similar HRs (150 mg versus 110 mg) for 
this outcome in RE-LY and RELY-ABLE are 0.97 (95% CI, 
0.88–1.07) and 1.07 (95% CI, 0.94–1.22), respectively.
There are several limitations of RELY-ABLE which include 
the following: only one-half of the patients continued from 
RE-LY to RELY-ABLE, no event adjudication was done in 
RELY-ABLE, and data analysis was not by the intention to 
treat. Patients enrolled in RELY-ABLE were different from 
those in RE-LY, and they may have been at lower risk of 
events. The main strengths are that RELY-ABLE more than 
doubled the duration of follow-up from that of RE-LY, and 
patients continued to receive the same dose of dabigatran 
Figure 2. Major bleeding.
Figure 3. Total mortality.
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(double-blind) as they had done in RE-LY. Registries of 
patients receiving new oral anticoagulants or warfarin also 
provide useful information about the long-term efficacy and 
safety of these agents. Once completed, these registries will 
provide more long-term safety data in populations of real-
world patients. One recently published registry reports a rate 
of intracranial bleeding on dabigatran of 0.3%/y that is con-
sistent with the low intracranial bleeding rates seen in RE-LY 
and RELY-ABLE with dabigatran 150 mg twice daily.9
In summary, the RELY-ABLE study provides additional 
safety information for a large cohort of patients continuing 
the same dose of dabigatran as assigned in the RE-LY trial 
during 2.3 years of additional treatment (total mean follow-up, 
4.3 years). During the additional 2.3 years of treatment, the 
rates of major events were not inconsistent with those seen in 
RE-LY. In the comparison of the 2 dabigatran doses in RELY-
ABLE, there was no significant difference in stroke or mor-
tality, but there was a higher rate of major bleeding with the 
higher dabigatran dose. There was no difference between the 
doses in net clinical benefit as estimated by the composite of 
stroke, bleeding, and death.
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CLINICAL PERSPECTIvE
Patients receiving dabigatran during the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial were 
eligible to continue their double-blind dose of dabigatran during an additional 2.3 years of follow-up as part of the Long-
term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial. The purpose of 
RELY-ABLE was to examine the long-term safety and efficacy of dabigatran. Not all countries or sites participated in RELY-
ABLE and ≈25% of eligible patients declined to enroll in RELY-ABLE; thus, just under half of the 12 091 patients receiving 
dabigatran in RE-LY were entered into the RELY-ABLE long-term extension study. No patients on warfarin were enrolled in 
RELY-ABLE. RELY-ABLE was an observational study rather than a definitive clinical trial. Patients entering RELY-ABLE 
were somewhat different from patients enrolled in RE-LY but who did not enter RELY-ABLE. During RELY-ABLE, rates 
of stroke and systemic embolism on dabigatran were similar to rates observed during RE-LY. This is also true for rates of 
other important ischemic and thrombotic outcomes and for the safety outcome of major bleeding. Rates of hemorrhagic 
stroke during RELY-ABLE remained very low as seen during RE-LY. During RELY-ABLE, there was a trend for a lower 
rate of stroke or systemic embolism on the higher dose of dabigatran and a higher rate of major bleeding on the higher dose 
of dabigatran. Total mortality on the 2 dabigatran groups was similar. Thus, RELY-ABLE provides some reassurance that 
the rates of stroke, major bleeding, and death seen during RE-LY on dabigatran are likely to continue during an additional 
2-year period of follow-up.
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SUPPLEMENTAL MATERIAL 
 
Supplemental Table 1:  Selected Baseline Patient Characteristics of RELY-ABLE Patients at time of RELY-ABLE Enrolment 
 150 mg 110 mg 
Age (years); mean, (SD) 73 (8) 73 (8) 
Systolic BP-sitting (mmHg); mean, (SD) 131 (18) 132 (18) 
Heart rate, sitting  beasts/minute); mean, 
(SD) 
72 (14) 72 (14) 
Male; number (%) 1911 (65) 1914(66) 
Persistent AF; number (%) 546 (19) 575 (20) 
Paroxysmal AF; number (%) 933 (32) 910 (31) 
Permanent AF; number (%) 1454 (50) 1424 (49) 
History of Hypertension; number (%) 2398 (82) 2384 (82) 
History of heart failure 689 (24) 655 (23) 
History of diabetes mellitus; number (%) 744 (25) 796 (27) 
History of  CAD; number (%) 938 (32) 919 (32) 
Baseline use of beta blocker; number (%) 1877 (64) 1901 (65) 
Baseline use of Statin; number (%) 1515 (52) 1515 (52) 
Baseline use of ACE inhibitor; number (%) 1270 (43) 1224 (42) 
Baseline use of ARB; number (%) 768 (26) 811 (28) 
Supplemental Figure 1 - RELY-ABLE: Time to Serious Adverse Event 
 
 Supplemental Figure 2 – RELY-ABLE: time to Permanent Discontinuation of Study Medication 
 
  
Supplemental Figure 2: Serious Adverse Events in RELY-ABLE by Organ Class 
System Organ Class 
110 mg 150 mg 
N % N % 
Participants  2914 100.0  2937 100.0 
Total Patient with SAE   982  33.7  1067  36.3 
Blood and lymphatic system disorders    42   1.4    49   1.7 
Cardiac disorders   323  11.1   368  12.5 
Congenital, familial and genetic disorders     .    .     1   0.0 
Ear and labyrinth disorders     8   0.3     6   0.2 
Endocrine disorders     3   0.1     4   0.1 
Eye disorders    17   0.6    18   0.6 
Gastrointestinal disorders   145   5.0   148   5.0 
General disorders and administration site conditions    87   3.0    87   3.0 
Hepatobiliary disorders    32   1.1    18   0.6 
Immune system disorders     2   0.1     1   0.0 
Infections and infestations   225   7.7   240   8.2 
Injury, poisoning and procedural complications   108   3.7   115   3.9 
Investigations    20   0.7    13   0.4 
Metabolism and nutrition disorders    41   1.4    58   2.0 
Musculoskeletal and connective tissue disorders    73   2.5    95   3.2 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)   126   4.3   117   4.0 
Nervous system disorders    91   3.1    86   2.9 
Psychiatric disorders    16   0.5    19   0.6 
Renal and urinary disorders    53   1.8    58   2.0 
Reproductive system and breast disorders    16   0.5    14   0.5 
Respiratory, thoracic and mediastinal disorders   104   3.6   111   3.8 
Skin and subcutaneous tissue disorders    12   0.4     5   0.2 
Social circumstances     1   0.0     1   0.0 
Surgical and medical procedures     3   0.1     2   0.1 
Vascular disorders    64   2.2    64   2.2 
 
